University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD)
17.5.2022 14:05:00 EEST | Business Wire | Press release
The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005065/en/
(Photo: Business Wire)
The trial is being led by principal investigator Mathew Rizzo, M.D., the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at Nebraska Medicine.
The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA).
(Clinical Trials.gov Identifier NCT05269459)
“This is our second clinical trial targeting PTSD. We are excited that UNMC’s research team has partnered with us to evaluate our promising drug for this very debilitating condition,” said Sohail R. Zaidi , ANANDA’s Chief Executive Officer. “It is an important step in our efforts to provide patients with PTSD with potentially improved therapeutic options.”
“Advancing evidence-based research into new therapeutics to provide a large PTSD patient population with new innovative treatment options is a key objective for our research team,” Dr. Rizzo said. “We are delighted to be collaborating with ANANDA Scientific on this trial.”
Dr. Rizzo also is the director of the National Institutes of Health’s Great Plains IDeA Clinical and Translational Research Network. He chairs the executive committee of the American Brain Coalition which advocates to advance research for neurological cures.
Dr. Rizzo’s research team will include Jennifer Merickel, Ph.D., Cognitive Neuroscientist and Assistant Professor in the UNMC Department of Neurological Sciences and Brigette Vaughan, an Advanced Practice Registered Nurse, Clinician and Researcher in the UNMC Department of Psychiatry.
This phase II double-blind, placebo controlled, randomized clinical study is planning to enroll 240 participants to provide rigorous clinical and real-world evaluation of the efficacy and safety of Nantheia™ ATL5.
ABOUT NANTHEIA™ ATL5
Nantheia™ ATL5 is an investigational drug that uses cannabidiol in ANANDA’s propriety Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness and stability of cannabidiol. Nantheia™ ATL5 is an oral product with 100mg cannabidiol per softgel capsule.
ABOUT University of Nebraska Medical Center
As Nebraska’s only public academic health sciences center, UNMC is committed to the education of a 21st century health care work force, to finding cures and treatments for devastating diseases, to providing the best care for patients, and to serving the state and its communities through award-winning outreach. UNMC has six colleges and two institutes, serving more than 4,200 students in two dozen programs. Researchers at UNMC perform cutting-edge research in neurological sciences, oncology, infectious disease, and other key areas.
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA). The company employs patented delivery technology to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its clinical portfolio. Consistent with its strong research-based data, the company has a growing pipeline of nutraceutical over-the-counter products. ANANDA has successfully launched these products in the U.S., Australia, and the U.K., with expansion into additional markets such as the EU, China, Africa, and other countries in Asia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005065/en/
Contact information
ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BioLab Holdings Launches EmeraNova™ to Advance the Future of Tissue Restoration15.10.2026 18:00:00 EEST | Press release
BioLab Holdings announced today a new, larger mission with the launch of EmeraNova™, a new corporate identity that reflects a broader ambition to advance tissue restoration across specialties, healing phases, and care settings. The launch marks the company’s efforts to build a global platform focused on identifying promising technologies and accelerating their path into clinical practice. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015721831/en/ EmeraNova seeks partners around the world to bring promising technologies to market quickly and equip clinicians with advanced, effective solutions. EmeraNova represents a vision to pursue emerging (Emer) and new (Nova) technologies by building an expanding toolbox of tissue restoration solutions, world-class support, and ways to bring together expert voices and clinical insights that will help shape what comes next. The company’s roots in chronic wound care will inform its fut
Body of Waves , a New Artwork Only at teamLab Planets TOKYO, Unveiled15.10.2026 18:00:00 EEST | Press release
teamLab Planets TOKYO (hereinafter referred to as “teamLab Planets”) has unveiled Body of Waves, a new artwork in which visitors enter a soft sculpture with their entire bodies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014474897/en/ teamLab, Body of Waves, 2026, from the series Soft Black Hole - Your Body Becomes a Space that Influences Another Body, 2016-© teamLab *Shot in real space. No AI or CGI. In addition, Existence in the Flow Creates Vortices—where vortices are created behind people as they climb against the flow—and Waterfall of Ephemeral Crystals—where shining particles cascade down to create a waterfall of light particles—have also evolved, further expanding the experience at teamLab Planets. New Artwork Body of Waves As you walk, your feet sink. This force is transmitted to the large, soft and flexible sculpture spreading across the floor, causing the sculpture to physically deform. The force generated b
CTIBIOTECH™ Announces Strategic Partnership and MOU With Beijing Vital River to Advance Preclinical Biomedical Innovation in China15.10.2026 17:59:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today announces the signing of a Memorandum of Understanding (MOU) and strategic partnership with Beijing Vital River, a Charles River company and provider of research models and associated preclinical services in China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014604195/en/ CTIBIOTECH signs strategic partnership with Beijing Vital River, a Charles River Laboratories company for commercialization of human tissue bioassays and New Approach Methodologies (NAMs) in Popular Republic of China The agreement was signed in Shanghai during the Shanghai – Auvergne-Rhône-Alpes Economic Dialogue, organized by the Nouvel Institut Franco-Chinois (NIFC), as part of the official Auvergne-Rhône-Alpes Region delegation to China. This alliance is designed to bring CTIBIOTECH™'s unique p
Navan Unveils New Ways to Book, Expense, and Travel at Navigate Europe 202615.10.2026 17:30:00 EEST | Press release
Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, unveiled a new set of capabilities and product updates at Navigate Europe, its flagship customer conference. The updates bring Navan into more workplace tools, expand card issuing to new currencies, and simplify guest reimbursement, all while giving businesses greater visibility and control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015250476/en/ “Business never stands still. Our customers are constantly expanding and expecting more value, which is why we continue to innovate and elevate every part of the employee experience,” said Michael Riegel, Chief Customer Officer at Navan. “We’ve spent years building the global technology infrastructure and expertise to make travel and expense work better. These new capabilities will support more users in more ways than ever before, all from one connected platform that moves as fast as they do.”
FlightSafety International to Deliver New Embraer E190-E2 Full-Flight Simulator to Azul Brazilian Airlines15.10.2026 17:05:00 EEST | Press release
FlightSafety International Inc. (FSI), the global leader in aviation training and simulation technology, today announced an agreement with Azul Brazilian Airlines to design and manufacture a new Embraer E190-300 (E190-E2) Level D Full-Flight Simulator. Anticipated for delivery in late 2027, the simulator will expand Azul’s pilot training capabilities at its training center in Campinas, São Paulo, Brazil. “Our partnership with Azul reflects a shared commitment to advancing aviation training and safety,” said Michele Posey, Executive Vice President, Sales, FlightSafety International. “This new simulator will provide Azul pilots with a highly realistic training environment that supports the development of critical skills and prepares them for the demands of commercial flight operations.” “This new simulator represents another important investment in Azul’s operational excellence and long-term growth strategy. Expanding our training capabilities ensures that we continue to prepare our pilo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom